CER Will Accelerate Copay Incentives In Private Coverage, United Exec Says
Executive Summary
The increasing availability of comparative effectiveness data on drug treatments will foster broader use of copay structures that discourage patients from seeking higher cost treatments that offer no real benefit over lower cost drugs, UnitedHealthcare Senior VP-Oncology Lee Newcomer predicted at a conference on CER and personalized medicine held at the National Institutes of Health Oct. 20.